



Press release

Gain of pharmaceutical establishment status

Dijon, 29 January 2019

CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company developing and soon to market a portfolio of drugs for use in emergency situations, announces that it has obtained the status of pharmaceutical establishment.

Patrick Alexandre, CEO of Crossject, said: *"We are proud to have obtained the status of pharmaceutical establishment, which reflects the efforts made by Crossject and all its employees in the implementation of our Quality policy. The company meets the level of quality set by drug manufacturing regulations."*

On 25 January 2019, the French National Agency for the Safety of Medicines and Health Products (ANSM) granted Crossject the authorisation to open a pharmaceutical establishment (manufacturer activity). This authorisation will allow Crossject to certify clinical batches and to perform in its laboratories quality controls on finished products for human use.



Contacts:

Crossject
Patrick Alexandre
info@crossject.com

Investor relations
CM-CIC Market Solutions
Catherine Couanau +33 (0)1 53 48 81 97
catherine.couanau@cmcic.fr

Press relations
Buzz & Compagnie
Mélanie Voisard +33 (0)3 80 43 54 89
melanie.voisard@buzzetcompagnie.com
Audrey Lachat +33 (0)3 80 43 54 89
audrey.lachat@buzzetcompagnie.com

About CROSSJECT · www.crossject.com

Crossject (ISIN: FR0011716265; Ticker: ALCJ; LEI: 969500W1VTFNL2D85A65) is developing and is soon to market a portfolio of drugs dedicated to emergency situations: epilepsy, severe migraine, allergic shock, overdose and asthma attack. Thanks to its patented needle-free self-injection system, Crossject aims to become the world leader in self-administered emergency drugs. The company has been listed on the Euronext Growth market in Paris since 2014, and has notably received financing from Bpifrance.